Blood cancers

Induction therapy response can’t stratify MM patients away from ASCT

Depth of response to induction therapy is likely not sufficient to identify patients who can defer autologous stem cell transplantation (ASCT) in multiple myeloma, a new study finds. Patients with certain characteristics may have good outcomes with deferred ASCT, but the study was too small to make firm conclusions. “The benefit of ASCT is related ...

Already a member?

Login to keep reading.

© 2021 the limbic